Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

About this Publication
Title
Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Pubmed ID
19568244 (View this publication on the PubMed website)
Publication
Br. J. Cancer. 2009 Aug; Volume 101 (Issue 3): Pages 522-5
Authors
Ahn J, Moore SC, Albanes D, Huang WY, Leitzmann MF, Hayes RB, Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Project Team
Affiliations
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20852, USA. Jiyoung.Ahn@NYUMC.org
Abstract

BACKGROUND: The relationship between prostate cancer and height is uncertain.

METHODS: We prospectively examined the association of height with prostate cancer among 34,268 men in the prostate, lung, colorectal, and ovarian cancer trial. Anthropometry was assessed at baseline and 2144 incident prostate cancer cases were identified upto 8.9 years of follow-up.

RESULTS: Overall, tallness was not associated with the risk of prostate cancer or with the risk of non-aggressive disease, but the risk for aggressive prostate cancer tended to be greater in taller men (Gleason score > or = 7 or stage > or = III; P trend=0.05; relative risk (RR) for 190 cm + vs < or = 170 cm = 1.39, 95% confidence interval (95% CI): 0.96-2.01). This association was largely limited to men below the age of 65 years (P trend=0.008; RR for 190 cm + vs < or = 170 cm = 1.76, 95% CI: 1.06-2.93; P for interaction=0.009), although the number of cases was small and risk estimates were somewhat unstable.

CONCLUSION: The results of this large prospective prostate cancer screening trial suggest that tallness is associated with increased risk for younger onset aggressive prostate cancer.

Related CDAS Studies